Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Nykode Therapeutics AS's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was -61.15%.
As of today (2026-07-16), Nykode Therapeutics AS's WACC % is 8.32%. Nykode Therapeutics AS's ROC % is -53.75% (calculated using TTM income statement data).
Nykode Therapeutics AS earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Nykode Therapeutics AS (CHIX:NYKDo) ROC % Explanation
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Nykode Therapeutics AS's WACC % is 8.32%. Nykode Therapeutics AS's ROC % is -53.75% (calculated using TTM income statement data).
Nykode Therapeutics AS earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Operating Income data used here is four times the quarterly (Mar. 2026) data.
The tax rate is limited to between 0% and 100%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nykode Therapeutics AS (CHIX:NYKDO) has a ROC % of -61.15% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Nykode Therapeutics AS and its competitors.
Is Nykode Therapeutics AS's ROC % too high?
Nykode Therapeutics AS's current ROC % is -61.15%. Overall, Nykode Therapeutics AS has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's ROC % compare to VRTX and REGN?
Nykode Therapeutics AS's ROC % of -61.15% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Nykode Therapeutics AS and its competitors. Nykode Therapeutics AS's current ROC % is -61.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Nykode Therapeutics AS (CHIX:NYKDO) has a current ROC % of -61.15%. The stock's GF Value™ is kr42.15, compared to a current price of kr18.69 — trading 55.7% below its estimated fair value. The current ROC % is -61.15%. Nykode Therapeutics AS's overall GF Score™ is 48/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Nykode Therapeutics AS (CHIX:NYKDO), the current ROC % is -61.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nykode Therapeutics AS (CHIX:NYKDO) Overvalued in 2026?
Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued.
The current stock price of kr18.69 is trading 55.7% below its estimated GF Value™ of kr42.15.
Key valuation signals for CHIX:NYKDO:
ROC %: -61.15%
GF Value™: kr42.15 vs. price of kr18.69 (55.7% below fair value)
No single metric tells the full story. See the CHIX:NYKDO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
48GF Score
Get the complete analysis for CHIX:NYKDO
ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:NYKDO has been successfully added to your 
